Retraction
EFFICACY, SAFETY, AND TOLERABILITY OF OMILANCOR IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS
Paper Information
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1093/ibd/izac055Additional Notes:
This article and withdrawal have unique DOIs and appear in a different journal, but the PDF for the article is the same article/abstract in Gastroenterology. Cf. RW entry at http://retractiondatabase.org/RetractionEdit.aspx?RID=37213.
Citations (1)
1
Total Citations1
Post-Retraction(100.0%)
0
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
0
Within 1 year
0
After 2+ years
438
Days since retraction (latest)
Oral Omilancor Treatment Ameliorates <i>Clostridioides difficile</i> Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation
Nuria Tubau‐Juni, Josep Bassaganya-Riera, Andrew Leber et al. (5 authors)
Inflammatory Bowel Diseases
Published: Jul 2023
2 citations
2 citations
438 days after retraction
Quick Stats
Total Citations:
1
Years Since Retraction:
3.6 years
Open Access:
Yes
Last Checked:
Jul 24, 2025